$1.2 million for preventing and managing chronic diseases in Quebec - The FRQS, MSSS and Pfizer announce funding for two chronic

$1.2 million for preventing and managing chronic diseases in Quebec - The 
FRQS, MSSS and Pfizer announce funding for two chronic disease research 
projects 
MONTREAL, March 5, 2013 /CNW Telbec/ - The Fonds de recherche du Québec - 
Santé (FRQS), in partnership with the Quebec Ministry of Health and Social 
Services (MSSS) and the pharmaceutical company Pfizer Canada, announces the 
second series of projects chosen under the Pfizer-FRQS-MSSS Chronic Disease 
Fund. 
Created thanks to an investment of $5 million from Pfizer Canada, this 
FRQS-coordinated research grant program is aimed at evaluating and funding 
chronic disease prevention and management initiatives, fostering, where 
appropriate, their implementation throughout Quebec, and making our healthcare 
system more efficient. 
Two of the projects submitted were recommended for funding, namely, those of 
the CSSS de Chicoutimi and the CSSS de l'Ouest-de-l'Île. This announcement 
represents investments totalling more than $1.2 million over the next two 
years. 
All the projects submitted to the Pfizer-FRQS-MSSS Chronic Disease Fund had to 
be in line with the Ministry of Health and Social Services' chronic disease 
goals, be primary-care initiatives for promoting the integration of chronic 
disease prevention and management, and focus on changing clinical practices. 
In accordance with the FRQS's current rules and procedures, the applications 
were examined by a scientific review committee consisting of experts from 
scientific and clinical settings. 
Primary-care management of vulnerable chronic disease patients
Spearheaded by the CSSS de Chicoutimi and the CSSS Lac-Saint-Jean-Est in Alma, 
the first project, named V1SAGES, is aimed at implementing and evaluating a 
primary-care case-management and self-management intervention for highly 
vulnerable chronic disease patients. To this end, an intervention will be 
implemented in four family medicine groups (FMGs) in Saguenay-Lac-Saint-Jean. 
The intervention will involve nurse-led case management and self-management 
support meetings. This project will receive a grant of $624,972 over two years. 
An integrated, primary-care chronic pain prevention and management network
The goal of the second project, headed by the CSSS de l'Ouest-de-l'Île, is to 
implement and evaluate an integrated, primary-care chronic pain prevention and 
management network. The objective is to expand an integrated, patient-centred, 
interdisciplinary program for the prevention and management of subacute low 
back pain in which the intensity of the intervention is tailored to the 
patient's health. More than 1200 patients will be followed on the territories 
of two Montreal CSSSs (Ouest-de-l'Île, Cavendish), one CSSS in Abitibi and 
one in the Montérégie. This project will receive a grant of $621,250 over 
two years. 
"We're very happy to support these innovative projects, thanks to the 
collaboration of MSSS and Pfizer Canada. Chronic diseases pose a significant 
challenge to all of Quebec society. These unique projects, which include both 
a clinical component and an evaluative research component, are providing an 
opportunity to recognize and disseminate original chronic disease prevention 
and management initiatives throughout Quebec," says Dr. Renaldo Battista, 
Scientific Director of the Fonds de recherche du Québec - Santé. 
"Pfizer Canada is firmly committed to discovering new ways to improve people's 
health and, as such, is proud to partner with the FRQS and MSSS to stimulate 
innovation and the sharing of good practices and tools created to facilitate 
primary care for Quebec's chronic disease patients," notes Dr. Bernard 
Prigent, Vice-President and Medical Director of Pfizer Canada. 
About the Fonds de recherche du Québec - Santé (FRQS)
The mission of the Fonds de la recherche du Québec - Santé (FRQS), which 
reports to the Minister of Higher Education, Research, Science and Technology, 
is to support health research in order to foster the wellness of Quebecers. 
Its mandate is to promote and financially support this research, to share 
knowledge and train researchers, as well as to establish partnerships 
necessary for the development of Quebec's research and innovation system and 
advance the research internationally. For additional information visit: 
www.frqs.gouv.qc.ca. 
About Pfizer Canada Inc.
Pfizer Canada Inc. is the Canadian division of Pfizer Inc., one of the world's 
leading biopharmaceutical companies. Pfizer Canada is one of the largest 
contributors to health research in Canada. Pfizer's diversified healthcare 
portfolio includes human and animal biologics, small-molecule medicines and 
vaccines, nutritional products and many of the world's best-known consumer 
products. 
Every day, Pfizer Canada employees work to advance wellness, prevention, 
treatments and cures that challenge the most feared diseases of our time. We 
apply science and our global resources to improve the health and well-being of 
Canadians at every stage of life. Our commitment is reflected in everything 
Pfizer does, from our disease awareness initiatives to our community 
partnerships, to our belief that it takes more than medication to be truly 
healthy. To learn more about Pfizer's More Than Medication philosophy and 
programs, visit morethanmedication.ca. To learn more about Pfizer Canada, 
visit pfizer.ca. 
Michelle Dubuc FRQS 514-873-2114, ext.1235 michelle.dubuc@frq.gouv.qc.ca 
Julie-Catherine Racine Pfizer Canada 1-866-973-4937 
julie-catherine.racine@pfizer.com  
SOURCE: Fonds de recherche du Québec - Santé 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/March2013/05/c2152.html 
CO: Fonds de recherche du Québec - Santé
ST: Quebec
NI: HEA MTC HEA  
-0- Mar/05/2013 12:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.